The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses
Ruszniewski PB, Caplin ME, Kunz PL, Bodei L, Hendifar AE, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Demange A, Mutevelic S, Krenning EP, Strosberg JR (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S911-S912
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2021.08.184
Authors with CRIS profile
Involved external institutions
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Royal Free Hospital
United Kingdom (GB)
Yale University
United States (USA) (US)
Memorial Sloan Kettering Cancer Center
United States (USA) (US)
Cedars-Sinai Medical Center
United States (USA) (US)
Oregon Health and Science University (OSHU)
United States (USA) (US)
Icahn School of Medicine at Mount Sinai
United States (USA) (US)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
MD Anderson Cancer Center Madrid
Spain (ES)
Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven
Belgium (BE)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Instituto Português de Oncologia Francisco Gentil (IPO) / Portuguese Oncology Institute
Portugal (PT)
Novartis AG
Switzerland (CH)
Erasmus University Medical Center (MC)
Netherlands (NL)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
France (FR)
Royal Free Hospital
United Kingdom (GB)
Yale University
United States (USA) (US)
Memorial Sloan Kettering Cancer Center
United States (USA) (US)
Cedars-Sinai Medical Center
United States (USA) (US)
Oregon Health and Science University (OSHU)
United States (USA) (US)
Icahn School of Medicine at Mount Sinai
United States (USA) (US)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
MD Anderson Cancer Center Madrid
Spain (ES)
Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven
Belgium (BE)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Instituto Português de Oncologia Francisco Gentil (IPO) / Portuguese Oncology Institute
Portugal (PT)
Novartis AG
Switzerland (CH)
Erasmus University Medical Center (MC)
Netherlands (NL)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
How to cite
APA:
Ruszniewski, P.B., Caplin, M.E., Kunz, P.L., Bodei, L., Hendifar, A.E., Mittra, E.,... Strosberg, J.R. (2021). The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses. In ANNALS OF ONCOLOGY (pp. S911-S912). AMSTERDAM: ELSEVIER.
MLA:
Ruszniewski, P. B., et al. "The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. S911-S912.
BibTeX: Download